Diagnostic Platform Jumps as Ebola Response Readiness Takes Center Stage

2026-05-19 11:04:00 ET

Global public health systems have become increasingly focused on rapid diagnostic readiness since the COVID-19 pandemic exposed the risks of delayed outbreak detection and centralized testing bottlenecks. As emerging infectious disease threats continue to trigger international emergency responses, companies with the ability to quickly develop and deploy molecular diagnostic assays are drawing renewed investor attention.

Shares of Co-Diagnostics, Inc. ( NASDAQ: CODX ) are surging Tuesday after the molecular diagnostics company announced it has completed the assay development strategy for the Bundibugyo virus (BDBV), the strain of Ebola currently driving an outbreak in the Democratic Republic of the Congo and Uganda.

Co-Diagnostics develops PCR-based diagnostic technologies designed for both centralized laboratory settings and decentralized point-of-care applications. The company’s broader Co-Dx PCR platform, which includes its PCR Home and PCR Pro devices along with supporting software infrastructure, remains under FDA review and is not yet commercially available.

The announcement follows a May 17 declaration from the World Health Organization classifying the Ebola outbreak as a Public Health Emergency of International Concern. According to the WHO, eight laboratory-confirmed cases, 246 suspected cases, and 80 suspected deaths had been reported in the Democratic Republic of the Congo, alongside two confirmed cases and one death in Uganda.

The U.S. Centers for Disease Control and Prevention has also responded with enhanced screening and monitoring guidance for travelers arriving from affected regions, including increased traveler monitoring, contact tracing coordination, and elevated hospital preparedness measures.

Co-Diagnostics said it has completed the strategic framework necessary to rapidly advance development of a BDBV assay should deployment become necessary.

“We are pleased to report that we have completed the assay development strategy for BDBV, and should a situation arise requiring the assay, we expect we would be well positioned to execute the strategy and rapidly make the test available,” said Chief Executive Officer Dwight Egan.

Management also used the announcement to reinforce the broader relevance of decentralized diagnostics and real-time outbreak visibility, highlighting the company’s cloud-connected PCR architecture as a potential differentiator in future public health responses.

The company indicated it remains open to collaboration with governmental and non-governmental agencies as outbreak conditions evolve and testing needs potentially expand.

Shares of CODX are up 85.6% to $2.57 in Tuesday morning trading.

Copyright © 2026 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

View more of this article on AllPennyStocks.com.

About AllPennyStocks.com Media, Inc.:

Founded in 1999, AllPennyStocks.com Media, Inc. is North America's largest and longest running website dedicated exclusively to micro-cap and small-cap insights.

Catering to both Canadian and U.S. markets, AllPennyStocks.com provides a wealth of resources and expert content designed for everyone, from beginner investors to seasoned traders.

AllPennyStocks.com's content is prominently featured across numerous top-tier financial platforms, reaching a broad audience of investors and industry professionals.

Contact:

AllPennyStocks.com Media, Inc.

Email: ads@allpennystocks.com

Phone: (800) 558-4560 Ext: 101